Die überschätzte Beeinflussung der Exazerbationsrate bei COPD durch Inhalativa (LABA, LAMA, ICS)

Zusammenfassung

Durch zahlreiche Studien ist belegt, dass inhalative, langwirksame Beta-2-Mimetika (LABA) und Anticholinergika (LAMA) sowie Steroide (ICS) die Exazerbationsrate bei COPD signifikant reduzieren. Allerdings konnte auch in aufwendigen und länger dauernden Studien nicht gezeigt werden, dass diese Reduktion der Exazerbation auch die Lebenserwartung verlängert. Im Gegensatz dazu zeigen zahlreiche Studien, dass die Lebenserwartung mit zunehmender Schwere und Häufigkeit der Exazerbation vermindert wird.

In dieser Übersicht werden diese Studien gegenübergestellt und die Relevanz der Reduktion der Exazerbationsraten durch LABA, LAMA und ICS durch Bewertung ihrer Effektstärke mittels Cohen’s d bewertet. Dabei zeigt sich in den Studien ein gleiches Muster. Die Reduktion der Exazerbationsrate zeigt nur bei den geringen Schweregraden einen kleinen Effekt (Cohen’s d max. 0,21). Bei Exazerbation mit höherem Schweregrad und bei Vergleich der Substanzen untereinander fällt Cohen’s d unter 0,1, was zeigt, dass die Wirkung der Medikamente klinisch praktisch bedeutungslos ist. Die Wirkung von LABA, LAMA und ICS auf die Exazerbationsrate bei COPD ist deutlich überschätzt.

Abstract

Numerous studies have shown that exacerbation rates in COPD can be significantly reduced by long acting beta-2-agonists (LABA), long acting anticholinergic agents (LAMA) and inhaled steroids (ICS). Elaborate and extensive investigations however failed to prove that the reduction in exacerbation rates leads to life prolongation. As opposed to this, numerous studies have shown a reduction in life expectancy with increasing number and severity of exacerbations.

This review aimed at comparing these studies and to elaborate the relevance and reduction of exacerbations rates by LABA, LAMA and ICS application through effect size calculation by means of Cohens’ d. These studies display a common pattern. The reduction of exacerbation rates is only being achieved for less severe exacerbations (Cohens’ d max. 0.21). For more severe exacerbations and for the comparison of different substances Cohens’ d remains below 0.1, indicating that the effect of the medications is practically irrelevant. The impact of LABA’s, LAMA’s and ICS on exacerbation rates in COPD patients is obviously overrated.

• Literatur

• 1 Fletcher C, Perto R, Tinker C, Speizer F. The Natural History of Chronic Bronchitis and Emphysema. Oxford: Oxford University Press; 1976
• 2 Hurst JR, Vestbo J, Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 16; 363: 1128-1138
• 3 Vestbo J, Edwards LD, Scanlon PD. et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011; 29;365: 1184-1192
• 4 Rennard SI, Locantore N, Delafont B. et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 2015; 12: 303-312
• 5 Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931
• 6 Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-963
• 7 Slenter RH, Sprooten RT, Kotz D. et al. Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration 2013; 85: 15-26
• 8 Ho TW, Tsai YJ, Ruan SY. et al. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One. 2014; 9;9: e114866.
• 9 Santibáñez M, Garrastazu R, Ruiz-Nuñez M. et al. Predictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease. PLoS One 2016; 30;11: e0158727
• 10 Wedzicha JA, Rabe KF, Martinez FJ. et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013; 143: 1302-1311
• 11 Mahler DA, O'Donnell DE. Recent advances in dyspnea. Chest 2015; 147: 232-241
• 12 O'Donnell DE, Webb KA, Harle I. et al. Pharmacological management of breathlessness in COPD: recent advances and hopes for the future. Expert Rev Respir Med 2016; 10: 823-834
• 13 Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015; 45: 525-537
• 14 Calverley PM, Anderson JA, Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789
• 15 Tashkin DP, Celli B, Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554
• 16 Wise RA, Anzueto A, Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 17;369: 1491-1501
• 17 Vestbo J, Anderson JA, Brook RD. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387: 1817-1826
• 18 Seemungal TA, Wilkinson TM, Hurst JR. et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147
• 19 Decramer M, Celli B, Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178
• 20 Wedzicha JA, Banerji D, Chapman KR. et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374: 2222-2234
• 21 Wyrwich KW, Tierney WM, Babu AN. et al. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res 2005; 40: 577-591
• 22 Jones PW, Beeh KM, Chapman KR. et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189: 250
• 23 Puhan MA, Chandra D, Mosenifar Z. et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011; 37: 784-790
• 24 Kon SS, Dilaver D, Mittal M. et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax 2014; 69: 793-798
• 25 Demeyer H, Burtin C, Hornikx M. et al. The Minimal Important Difference in Physical Activity in Patients with COPD. PLoS One 2016; 28;11: e0154587
• 26 Garcia-Aymerich J, Lange P, Benet M. et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-778
• 27 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391-398
• 28 Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 28: 681-686
• 29 Köhnlein T, Windisch W, Köhler D. et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698-705
• 30 Vestbo J, Anderson JA, Calverley PM. et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009; 64: 939-943